Drugs / bapineuzumab
bapineuzumab
also known as
AAB-001 · Eln115727 · AAB-001, Humanized 3D-6 Monoclonal Antibody · HUMANIZED 3D-6 MONOCLONAL ANTIBODY
Monoclonal antibody targets APP
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00397891 | Oct 2006 → Feb 2010 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01254773 | Dec 2010 → Jan 2013 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00916617 | Jun 2009 → Sep 2012 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00663026 | Nov 2008 → Oct 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00112073 | Apr 2005 → Nov 2008 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00174525 | Apr 2005 → Apr 2008 | Alzheimer disease | Pharmacology Research Institute | Unknown | No outcome recorded |
| Phase 36 trials · 4 missed | ||||||
| Phase 3 | NCT00998764 | Dec 2009 → Oct 2012 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00996918 | Dec 2009 → Nov 2012 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00667810 | Jun 2008 → Oct 2012 | Alzheimer disease | Pfizer | Terminated | Missed primary |
| Phase 3 | NCT00676143 | Jan 2008 → Oct 2012 | Alzheimer disease | Pfizer | Terminated | Missed primary |
| Phase 3 | NCT00574132 | Dec 2007 → Jun 2012 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Completed | Missed primary |
| Phase 3 | NCT00575055 | Dec 2007 → Apr 2012 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00606476 Comparator | Dec 2006 → Sep 2012 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00937352 Comparator | Jul 2009 → Sep 2012 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bapineuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00397891 ↗ |
| Known as | AAB-001 | “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered...” NCT01254773 ↗3“A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who...” NCT00937352 ↗ “Bapineuzumab (AAB 001) Administered Subcutaneously” NCT00663026 ↗ |
| Known as | AAB-001, Humanized 3D-6 Monoclonal Antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108576 ↗ |
| Known as | Eln115727 | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to...” NCT00667810 ↗2“A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who...” NCT00937352 ↗ “A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease” NCT00998764 ↗ |
| Known as | HUMANIZED 3D-6 MONOCLONAL ANTIBODY | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108576 ↗ |
| Modality | Monoclonal antibody | “bapineuzumab, a humanised monoclonal antibody directed against amyloid β” PMID 25669746 ↗ Feb 2015 |
| Route | Intravenous | “IV, Q13w” NCT00112073 ↗ |
| Target | APP | “Amyloid-beta A4 protein binding agent” CHEMBL2108576 ↗ |